A pared back three-drug salvage regimen for patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) who are ineligible for stem cell transplant provides outcomes ‘as good’ as a widely used four-drug regimen but with the benefit of reduced toxicity, according to an Australian study. Investigators from NSW, Victoria and Canberra who conducted the multicentre phase ...
Modified chemo regimen less toxic for transplant-ineligible lymphoma patients
By Sunalie Silva
30 Sep 2019